N6-2-(4-aminophenyl)ethyladenosine (APNEA), a putative adenosine A3 receptor agonist, enhances methamphetamine-induced dopamine outflow in rat striatum

Polish Journal of Pharmacology

Volumn 50, Issue 4-5, 1998, Pages 299-305

  Gołembiowska, Krystyna ^a   Zylewska, Alicja ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Adenosine A3 receptor; DA and glutamate release; Methamphetamine; Microdialysis; Rat striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 6 N [2 (4 AMINOPHENYL)ETHYL]ADENOSINE; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR STIMULATING AGENT; DOPAMINE; GLUTAMIC ACID; HOMOVANILLIC ACID; METHAMPHETAMINE; ADENOSINE; ADENOSINE RECEPTOR; CARDIOTONIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; N(6) 2 (4 AMINOPHENYL)ETHYLADENOSINE; N(6)-2-(4-AMINOPHENYL)ETHYLADENOSINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; INTRACEREBRAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NEUROTOXICITY; NONHUMAN; RAT; ANIMAL; DRUG EFFECT; DRUG INTERACTION; DRUG POTENTIATION; METABOLISM; SECRETION; VISUAL CORTEX; WISTAR RAT;

3,4-DIHYDROXYPHENYLACETIC ACID; ADENOSINE; ANIMALS; CARDIOTONIC AGENTS; DOPAMINE; DOPAMINE AGENTS; DRUG INTERACTIONS; DRUG SYNERGISM; GLUTAMIC ACID; HOMOVANILLIC ACID; MALE; METHAMPHETAMINE; MICRODIALYSIS; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A3; RECEPTORS, PURINERGIC P1; VISUAL CORTEX;

EID: 0031593348     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. 3 receptors in rat brain. Mol. Pharmacol., 1995, 48, 1038-1045.
2. Abekawa T., Ohmori T., Koyama T.: Effects of repeated administration of high dose of methamphetamine on dopamine and glutamate release in rat striatum and nucleus accumbens. Brain Res., 1994, 643, 276-281.
3. Borowsky B., Hoffman B. J.: Neurotransmitter transporters: molecular biology, function, and regulation. Int. Rev. Neurobiol., 1995, 38, 139-199.
4. Brunswick D. J., Benmansour S., Tejani-Butt S. M., Hauptmann M.: Effects of high-dose methamphetamine on monoamine uptake sites in rat brain measured by quantitative autoradiography. Synapse, 1992, 11, 287-293.
5. Delle Donne K. T., Sonsalla P. K.: Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation. J. Pharmacol. Exp. Ther., 1994, 27, 1320-1326.
6. Dixon A. K., Gubitz A. K., Sirinathsinghji D. J. S., Richardson P. J., Freeman T. C.: Tissue distribution of adenosine receptor mRNAs in the rat. Brit. J. Pharmacol., 1996, 118, 1461-1468.
7. Dragunow M., Faull R. L.: Neuroprotective effects of adenosine. Trends Pharmacol. Sci., 1988, 9, 193-194.
8. Fleckenstein A. E., Metzger R. R., Gibb J. W., Hanson G. R.: A rapid and reversible change in dopamine transporters induced by methamphetamine. Eur. J. Pharmacol., 1997, 323, R9-R10.
9. 3 receptors potentiate hippocampal calcium current by a PKA-dependent/PKC-independent pathway. Neuropharmacology, 1997, 36, 353-362.
10. Fredholm B. B., Abbracchio M. P., Burnstock G., Daly J. W., Harden T. K., Jacobson K. A., Leff P., Williams M.: IV. Nomenclature and classification of purinoceptors. Pharmacol. Rev., 1994, 46, 143-156.
11. 2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum. Brain Res., 1998, in press.
12. Gołembiowska K., Żylewska A.: Effect of endogenous adenosine on methamphetamine-induced dopamine release in rat striatum. Drug Develop. Res., 1998, 43, 69, abstr. 265.
13. Hagberg H., Andersson P., Lazarewicz J., Jacobson I., Butcher S., Sandberg M.: Extracellular adenosine, inosine, hypoxanthine and xanthine in relation to tissue nucleotides and purines in rat striatum during transient ischemia. J. Neurochem., 1987, 49, 227-231.
14. Hirata H., Ladenheim B., Carlson E., Epstein Ch., Cadet J. L.: Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain: attenuation in CuZn-superoxide dismutase transgenic mice. Brain Res., 1996, 714, 95-103.
15. 2 dopaminergic receptors mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res., 1995, 690, 264-268.
16. Imperato A., Di Chiara G.: Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. J. Neurosci., 1984, 4, 966-977.
17. Ishii H., Stanimirovic D. B., Chang C. J., Mrsulja B. B., Spatz M.: Dopamine metabolism and free-radical related mitochondrial injury during transient brain ischemia in gerbils. Neurochem. Res., 1993, 18, 1193-1201.
18. 3 receptors: novel ligands and paradoxical effects. Trends Pharmacol. Sci., 1998, 19, 184-191.
19. 3 receptors: design of selective ligands and therapeutic prospects. Drugs Future, 1995, 20, 689-699.
20. 3 adenosine receptors : mediation of behavioral depressant effects. FEEBS Lett., 1993, 336, 57-60.
21. Knecht R., Chang J.-Y.: Liquid chromatographic determination of amino acids after gas-phase hydrolysis and derivatization with (dimethylamino) azobenzenesulfonyl chloride. Anal. Chem., 1986, 58, 2375-2379.
22. Maura G., Giardi A., Raiter M.: Release-regulating D-2 dopamine receptors are located on striatal glutamatergic nerve terminals. J. Pharmacol. Exp. Ther., 1988, 247, 680-684.
23. 3 receptors regulate serotonin transport via nitric oxide and cAMP. J. Biol. Chem., 1994, 269, 27351-27356.
24. Nash J. F., Yamamoto B. K.: Methamphetamine neurotoxicity and striatal glutamate release: comparison to 3,4-methylenedioxymethamphetamine. Brain Res., 1992, 581, 237-243.
25. Phillis J. W., Wu P. H.: The role of adenosine and its nucleotides in central synaptic transmission. Prog. Neurobiol., 1981, 16, 187-239.
26. Ramkumar V., Stiles G. L., Beaven M. A., Ali H.: The A-3 adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. J. Biol. Chem., 1994, 268, 16887-16890.
27. Ricaurte G. A., Guillery R. W., Seiden K. S., Schuster C. R., Moore R. Y.:Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain. Brain Res., 1982, 235, 93-103
28. 125I]AB-MECA) labels multiple adenosine receptor subtypes in rat brain. Brain Res., 1997, 745, 10-20.
29. Shin Y., Daly J. W., Jacobson K. A.: Activation of phosphoinositide breakdown and elevation of intracellular calcium in rat RBL-2H3 mast cell line by adenosine analogs: involvement of A3-adenosine receptors? Drug Develop. Res., 1996, 39, 36-46.
30. Sonsalla P. K., Giovanni A., Sieber B. A., Delle Donne K. T., Manzino L.: Characteristics of dopaminergic neurotoxicity produced by MPTP and methamphetamine. Ann. N.Y. Acad. Sci., 1992, 648, 229-238.
31. Sonsalla P. K., Riordan D. E., Heikkila R. E.: Competitive and noncompetitive antagonists at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice. J. Pharmacol. Exp. Ther., 1991, 256, 506-512.
32. Stephans S. E., Yamamoto B. K.: Effect of repeated methamphetamine administration on dopamine and glutamate efflux in rat prefrontal cortex. Brain Res., 1995, 700, 99-106.
33. Van Calker D., Müller M., Hamprecht B.: Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem., 1979, 33, 999-1005
34. 3 receptor stimulation on seizures in mice. Eur. J. Pharmacol., 1995, 275, 23-29.
35. Von Lubitz D. K., Lin R. C., Popik P., Carter M. F., Jacobson K. A.: Adenosine A-3 receptor stimulation and cerebral ischemia. Eur. J. Pharmacol., 1994, 263, 59-67.
36. Weihmuller F. B., O'Dell S. J., Marshall J. F.: MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow. Synapse, 1992, 11, 155-163.
37. Yamamoto B. K., Davy S.: Dopaminergic modulation of glutamate release on striatum as measured by microdialysis. J. Neurochem., 1992, 58, 1736-1742.
38. 3 adenosine receptor. Proc. Nat. Acad. Sci. USA, 1992, 89, 7432-7436.